ArticleCardiovascular diabetology2024

Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control study.

Kai-Cheng Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.